Brind.
  1. A company has entered into a non-clinical evaluation agreement with NIAID, partnering with AFRRI on protocol design that meets FDA Animal Rule criteria.

Valion Bio Receives Fast Track Designation for Entolimod

1 report, 1 independent Updated Tue 15:15
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Valion Bio reported that its subsidiary, Velocity Bioworks, completed a 200-liter non-GMP production run of Entolimod at its San Antonio, Texas facility. The drug substance met all predefined acceptance criteria, and the company also received Fast Track designation for Entolimod from the FDA. The ongoing study is funded by the National Institute of Allergy and Infectious Diseases.

From californiatelegraph.com

Why it matters

Some supportBrind's analysis of the reports

The successful scale-up of the drug substance validates core manufacturing operations, representing a transition toward CGMP clinical trial material production. The Fast Track designation supports the continuation of the study funded by the National Institute of Allergy and Infectious Diseases.

A company entered into a non-clinical evaluation agreement with National Institute of Allergy and Infectious Diseases, partnering with Armed Forces Radiobiology Research Institute on protocol design that meets FDA Animal Rule criteria.

From californiatelegraph.com

Who's involved

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped